Top 100 medical and healthcare startups in UK
Mar 08, 2026
|
Like
16
1
Funding: $52M
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
Iksuda Therapeutics develops ADCs with enhanced tumor specificity. They incorporate tumor-specific, selective release and activation of payloads through mechanisms relevant to the target and tumor, thereby optimizing anticancer efficacy and improving patient safety. The company has also developed a new class of alkylating protein payloads, ProAlk. With their tailored properties to specific ADCs and broad applicability across various tumor types, Iksuda is currently developing a new ProAlk-ADC portfolio. The company's portfolio includes clinical trials against B-cell malignancies, breast cancer, gastric cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer and cervical cancer.
2
Funding: $50M
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
Enara Bio develops targeted cancer immunotherapies using its Dark Antigen discovery engine and optimized T-cell activator platform. Dark Antigens cluster - is a rich source of novel cancer targets derived from genomic regions previously considered "dark" or non-coding. The EDAPT platform helps to identify these dark targets. The company has also developed EnTiCE platform for creating bispecific T-cell activators against these identified targets to improve treatment outcomes for a wide range of cancer patients. Enara Bio's pipeline includes clinical trials against solid tumors, non-small cell lung cancer, melanoma, and ovarian cancer. The startup is backed by leading biotech investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital, and SV Health Investors.
3
Funding: $3.6M
ReactWise provides an artificial intelligence Co-Pilot that facilitates the optimization of chemical processes.
ReactWise provides an artificial intelligence Co-Pilot that facilitates the optimization of chemical processes.
4
Funding: £1.1B
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
Oxford Nanopore Technologies has developed the world's first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology.
5
Funding: $1.3B
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
CMR Surgical created #Versius: the next-generation universal robotic system for minimal access surgery.
6
Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
7
Funding: $1.2B
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease.
8
Funding: $1.1B
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
9
Funding: $1.1B
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
Autolus uses advanced CAR-T cell therapy to treat hematological malignancies and solid tumors. While CAR T-cell therapy has revolutionized cancer treatment, it can also cause significant immunotoxicity. Autolus has developed a novel CAR-construct with rapid binding kinetics that is similar to natural T cells and provides improved tolerability in patients with certain types of leukemia. Furthermore, Autolus addresses the issue of immunotoxicity through a personalized dosing approach. The company is also seeking to adopt CAR-T therapy to patients with acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, T-cell lymphoma and solid tumors. It is supporting several ongoing CAR-T clinical trials that are opening up new treatment options and offering new hope for these patients.
10
Funding: $601.7M
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
11
Funding: $474.4M
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
Exscientia is applying AI and big data processing to accelerate drug discovery and development.
12
Funding: $430M
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
HOLOGEN AI develops breakthrough technologies that deliver interventional intelligence in healthcare, improving the understanding, design, evaluation, and delivery of treatments.
13
Funding: $421.2M
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
COMPASS Pathways is advancing the drug, the active ingredient in magic mushrooms, for use in people with treatment-resistant depression.
14
Funding: $414M
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
Artios develops a pipeline of DNA damage response (DDR)-targeting cancer prospects, that is based on the idea that tumor cells use DDR pathways to manage DNA damage. By inhibiting key components of the DDR, a DDR inhibitor can kill cancerous cells while skipping healthy ones. Company's lead candidate, alnodesertib (DNA polymerase theta inhibitor) is intenede to treat pancreatic cancer, breast and third-line colorectal cancer. It has demonstrated durable responses in patients with eight different solid tumor types whose tumors had ATM deficiency. Artios’ pipeline also features a DDR inhibitor antibody-drug conjugate (DDR-ADC) discovery program
15
Funding: $411.7M
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
Quanta develops an advanced haemodialysis systems for use in the home and clinic.
16
Funding: $397.9M
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
Apollo Therapeutics provides funding & drug discovery expertise accelerating the best of British academic research to the clinic.
17
Funding: $383.3M
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
18
Funding: $322.6M
Huma offers a health platform used for remote patient monitoring and biological data gathering for preventative healthcare.
Huma offers a health platform used for remote patient monitoring and biological data gathering for preventative healthcare.
19
Funding: $322.6M
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
Medopad connects patients and providers in real time. It also collects data through wearables and lets patients send their data to healthcare professionals. The platform also offers providers and insurers ways to analyze large amounts of data using artificial intelligence and machine learning.
20
Funding: $302.1M
Freeline Therapeutics is a biopharmaceutical company specialising in developing liver directed gene therapies for bleeding disorders.
Freeline Therapeutics is a biopharmaceutical company specialising in developing liver directed gene therapies for bleeding disorders.
21
Funding: $292M
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
A leading British artificial intelligence company located in the knowledge quarter of London with a focus in health and drug development
22
Funding: $290.1M
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
Beacon Therapeutics is an ophthalmic gene therapy company to treat blinding retinal illnesses and restore and enhance eyesight.
23
Funding: $275.8M
Flo Health is a developer of Flo, the fastest growing AI-driven women’s health product that encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause).
Flo Health is a developer of Flo, the fastest growing AI-driven women’s health product that encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause).
25
Funding: $239.7M
PepGen is empowering nucleic acid therapeutics to go the distance and building neuromuscular and neurologic pipeline.
PepGen is empowering nucleic acid therapeutics to go the distance and building neuromuscular and neurologic pipeline.
26
Funding: $240M
Barinthus Biotherapeutics is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
Barinthus Biotherapeutics is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
27
Funding: $219.2M
Juvenescence AI is focused on developing drugs that were discovered by Artificial Intelligence Techniques.
Juvenescence AI is focused on developing drugs that were discovered by Artificial Intelligence Techniques.
28
Funding: $213M
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
Achilles Tx's mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells
29
Funding: $206.6M
YuLife is a provider of life insurance and policies providing income in the event of critical illness.
YuLife is a provider of life insurance and policies providing income in the event of critical illness.
30
Funding: $207M
OrganOx develops a revolutionary device for storing livers at normal body temperatures for extended periods of time. Following extensive pre-clinical studies and the successful completion of clinical studies, the product is now commercially available within the EU.
OrganOx develops a revolutionary device for storing livers at normal body temperatures for extended periods of time. Following extensive pre-clinical studies and the successful completion of clinical studies, the product is now commercially available within the EU.
31
Funding: $205.5M
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
32
Funding: $193.7M
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
MISSION Therapeutics offers a platform for the development of small molecule drugs that selectively target deubiquitylating enzymes (DUBs).
33
Funding: $192.5M
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
PsiOxus aims to be the world’s leading cancer gene therapy company, delivering medicines of value to patients with cancer.
35
Funding: $188M
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
Pheon Therapeutics is developing a portfolio of next-generation ADCs with the potential to treat difficult-to-treat solid tumors. Recognizing that there is no one-size-fits-all solution in ADC development, Pheon takes an adaptive approach to ADC development. Using monoclonal antibodies (mAbs) against both novel and clinically proven ADC targets and equipping them with either proprietary platform active substances with a novel mechanism of action or pre-existing linker combinations, Pheon precisely ensures the balance of safety and efficacy for each target. Pheon has assembled a world-class leadership team with two decades of ADC experience. The company is currently conducting Phase I clinical trials of its lead asset, which has demonstrated robust preclinical data, including in vivo efficacy, NHP safety and extensive expression profiling in tumors and healthy tissue.
36
Funding: $169.2M
Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
37
Funding: $168.7M
A breathalyzer for disease. Owlstone Medical has developed Breath Biopsy technology to identify non-invasive VOC biomarkers in breath.
A breathalyzer for disease. Owlstone Medical has developed Breath Biopsy technology to identify non-invasive VOC biomarkers in breath.
38
Funding: $166.4M
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
39
Funding: £128M
OMass Therapeutics develops new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry.
OMass Therapeutics develops new medicines against highly validated but inadequately drugged targets using novel biochemistry techniques, native mass spectrometry and custom chemistry.
40
Funding: $162.7M
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
41
Funding: £125M
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
42
Funding: $155.2M
Cambridge Epigenetix develops ground-breaking epigenetics tools for DNA methylation (5mC) and hydroxymethylation (5hmC) analysis.
Cambridge Epigenetix develops ground-breaking epigenetics tools for DNA methylation (5mC) and hydroxymethylation (5hmC) analysis.
43
Funding: $148.2M
Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment
Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment
45
Funding: $130.7M
Numan is a startup which aims to tackle your tackle problem erectile dysfunction.
Numan is a startup which aims to tackle your tackle problem erectile dysfunction.
46
Funding: $130M
MiroBio develops novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases. MiroBio's medicines will activate natural mechanisms to regain control of over-active immune responses triggering these diseases.
MiroBio develops novel, best-in-class therapeutics that bring significant benefits to patients suffering from a range of auto-immune diseases. MiroBio's medicines will activate natural mechanisms to regain control of over-active immune responses triggering these diseases.
47
Funding: $127.5M
Oviva is digitising the treatment of type 2 diabetes and obesity through our unique behaviour change platform. Oviva combines personalised dietary advice with a unique digital app and provides you with individual support for targeted dietary changes.
Oviva is digitising the treatment of type 2 diabetes and obesity through our unique behaviour change platform. Oviva combines personalised dietary advice with a unique digital app and provides you with individual support for targeted dietary changes.
48
Funding: $118M
Proximie is a secure software solution that expands virtual surgical collaboration enabling surgeons to share expertise through AR.
Proximie is a secure software solution that expands virtual surgical collaboration enabling surgeons to share expertise through AR.
49
Funding: $114.9M
Biotechnology company integrating artificial intelligence with expert pharmacology to discover treatments for rare diseases
Biotechnology company integrating artificial intelligence with expert pharmacology to discover treatments for rare diseases
50
Funding: $113.8M
Ultromics clinicians and engineers working together to set new standards for world-class cardiovascular diagnostic tools.
Ultromics clinicians and engineers working together to set new standards for world-class cardiovascular diagnostic tools.
